Tesamorelin

Target Visceral Fat & Metabolic Health at the Hormonal Level

Tesamorelin is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH), designed to stimulate the pituitary gland to release endogenous growth hormone (GH). By enhancing GH and downstream IGF-1 signaling, Tesamorelin has become a primary compound of interest in research focused on visceral fat reduction, metabolic optimization, and healthy aging.

Unlike direct GH administration, Tesamorelin works by supporting the body’s natural hormonal pathways—making it a widely studied compound for improving body composition while preserving lean tissue integrity.

Product features

• GHRH analog peptide — studied for stimulating natural GH and IGF-1 release.
• Lyophilized (freeze-dried) formulation — enhances stability and shelf life.
• Sterile 3 mL glass vial — designed to maintain compound integrity.
• Butyl rubber stopper — allows secure multi-access sealing.
• ETO-sterilized & depyrogenated — finished with tamper-evident aluminum flip-top.

Key benefits (Research Highlights)

• Visceral fat reduction — extensively studied for reducing visceral adipose tissue (VAT) while preserving subcutaneous fat.
• Metabolic optimization — GH-mediated pathways support improved lipid metabolism and energy utilization.
• Insulin sensitivity support — research indicates improvements in glucose handling and metabolic markers.
• Lean muscle preservation — GH and IGF-1 signaling help maintain muscle mass during caloric restriction or aging.
• Anti-aging & tissue health — GH activity is linked to skin elasticity, connective tissue repair, and cellular regeneration.
• Cognitive & neurological interest — emerging studies explore neurogenesis support and inflammation reduction in aging models.

Research reference: dosage ranges used in studies

Scientific literature evaluating Tesamorelin has explored specific quantity ranges and administration frequencies depending on research objectives related to visceral fat reduction, metabolic health, and GH pathway modulation.

Many studies reference consistent daily exposure over defined research cycles to evaluate hormonal signaling, lipid redistribution, and body composition outcomes. These values are provided strictly for educational and informational reference within a controlled research context.

These quantities do not represent usage instructions or recommendations.

Research reference: safety & tolerability observations

Across controlled clinical and preclinical research environments, Tesamorelin has generally demonstrated a favorable tolerability profile. Observations vary depending on study duration, hormonal sensitivity, and metabolic status.

• Transient injection-site responses reported in peptide administration studies
• Temporary fluid balance or GH-related signaling changes
• Hormonal adaptation responses observed during prolonged exposure

All safety-related information is derived from published research and is presented solely for transparency within a scientific context.

Need help choosing the right compound? Our consultation service is available to help determine whether Tesamorelin aligns with your fat-loss, metabolic, recovery, or longevity-focused research goals.

Disclaimer: For research purposes only. Not intended for human consumption. Information provided is for educational reference and does not constitute medical advice.